Drug intelligence / Profile preview

IN026

Development stage: Phase 1
Lead developer: Innorna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

IN026 is an investigational mRNA-based protein-replacement therapy developed by InnoRNA Biotech for the treatment of refractory gout. It utilizes a proprietary lipid nanoparticle (LNP) platform to deliver mRNA encoding the enzyme urate oxidase (uricase; UOX) to the liver. Once expressed, the UOX enzyme facilitates the systemic breakdown of uric acid into allantoin, a more soluble metabolite that is easily excreted. This approach aims to provide long-term disease control and represents a potential first-in-class mRNA therapy for chronic metabolic disorders.

Targets

UOX (Urate oxidase)

Beyond the preview

Go deeper on IN026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN026.

Explore the full profile